💻 New user accounts 💻 Feature1️⃣️: Personalizing your areas of interest 🔍 Select a trial, congress, or any relevant #multiplemyeloma disease areas to the 'Areas of interest' section; this content will be used to suggest further recommendations. loom.ly/jOAz-u0 #ASH23

Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management | American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10… #lymsm

Idiopathic erythrocytosis: A diagnostic and management challenge with emerging areas for exploration buff.ly/3uitUYy

📘Ya tenemos disponible para su descarga la actualización de la "Guía de práctica clínica para el DIAGNÓSTICO, TRATAMIENTO Y SEGUIMIENTO DEL LINFOMA DE HODGKIN 2023". Encuéntrala en la web de GELTAMO. GELTAMO @sehh_es SEHH Joven 💻geltamo.com/actividades-ci…

#Hematology Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the ⁦American Heart Association⁩ Association | ⁦Circulation⁩ #CardioOnc #bmtsm #survonc ahajournals.org/doi/full/10.11…

#Myeloma Paper of the Day: Response rate & EFS to 2nd line dara/bortez/dex in relapsed/refractory light chain AL #amyloidosis after initial bortez-based regime are better if prior response was CR/VGPR & if relapsed disease vs. inadequate prior response: pubmed.ncbi.nlm.nih.gov/38840512/.

Volume 2024 Issue 1 | Hematology, ASH Education Program | American Society of Hematology #ASH24 ⁦Mohamad Mohty⁩ ⁦IACH⁩ ashpublications.org/hematology/iss…

PICC Line Insertion: Comprehensive Review for Hematology 1️⃣ Indications for PICC Lines in Hematology •Chemotherapy Requiring PICC: •Vesicant drugs: Anthracyclines (e.g., Doxorubicin, Daunorubicin), Vincristine, Cisplatin. •Irritants: Hypertonic saline, parenteral nutrition,

#NuevaFotoDePerfil

Is risk-adapted therapy ready for prime time in Multiple Myeloma? Check out our recent review looking at risk definitions and MRD-guided therapy for MM Shaji Kumar @MayoMyeloma Free article link here: tandfonline.com/eprint/8MGWA8G…

Solitary plasmacytoma. One lesion, but 3 possible entities with differing prognosis in the differential diagnosis. Outcomes and management. ⁦Mayo Myeloma⁩ ⁦Blood Advances⁩ ⁦ASH⁩ ashpublications.org/bloodadvances/…

🧵 #MultipleMyeloma 2025 Mayo Clinic Flowcharts Summary 🩸🧬 By Dr. S. Vincent Rajkumar #MM #Oncology #ASCT #Bispecifics #Hematology 🧪 ⸻ 1️⃣ Newly Diagnosed, Transplant-Eligible 💠 Standard-Risk → Induction: Dara-VRd or Isa-VRd x 3–4 → Early ASCT or Stem cell cryo + 4–5 more

The power of cellular immunotherapy ! Impressive results! Congratulations ! ⁦Journal of Clinical Oncology⁩ ⁦IACH⁩ ⁦COMy⁩ ⁦ASCO⁩